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Tangential Flow Filtration and Scalability for               
Gene Therapy Virus Purification (AAV)
2• Gene therapies are becoming more common, practical and effective
- diabetes, hemophilia, cystic fibrosis, cancer, SMA, Huntigton’s, 
• Advantages of AAV/ADV: easy to concentrate and high rates of infection
- many cell types, dividing/non-dividing
• Downstream purification is a necessary tool in recovering final product 
• Tangential flow filtration (TFF) clears low molecular weight impurities (i.e. less than 
filter retention rating) and buffer exchange is essential to stability
Introduction 
3Abstract
Pall Biotech has linearly scalable tangential flow filtration (TFF) technology that can 
process volume ranges from less than 1 L to over 2000 L
Programmable skids are available for industrial scale volumes 
 In this presentation, TFF linear scalability of up to 200 L is covered starting from a 
9 L initial volume and maintaining similar pressures, processing times and yields at 
all scales. Yield was upwards of 90% for both runs
Using this scalable technology, Pall Biotech enables biologics companies to serve 
their target markets by going to clinical trials and to commercial scale 
manufacturing successfully 
4Basic TFF System Components
● Membranes
● Pump
● Tank
● Piping
● Pressure gauge
Basic Components
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6Cell culture harvest of AAV 
SupraCap100 V100P depth filter (2-4 microns)
Stax with V100P media for large scale 
Manual TFF assembly (small scale TFF)
0.1 m2 surface area, 300 kDa Pall Centramate™ TFF cassette 
2.5 m2 surface area, 300 kDa Pall Centrasette™ TFF cassette 
Allegro single-use TFF system (CS1000)
Allegro single-use biocontainer 
Materials
7Cell culture material was clarified through a 2-4 micron pore size depth filter for 
large and small scale using V100P depth media. Depth filter was flushed with 25 
mM Tris, 100 mM NaCl, pH 7.5 to maximize recovery
Filtrate from the previous step was concentrated 10x in small (0.1m2) and large 
(2.5m2) scale. TFF set up and buffer exchanged 5x into 25 mM Tris, 100 mM NaCl, 
0.005% Tween 20, pH 7.5
Supor® EKV membrane Kleenpak™ capsule was used for sterilizing grade filtration 
at the end of the TFF step
SDS-Page was used to examine impurity clearance per process step
qPCR was used to determine titer
Methods 
8• Pall scale-up TFF systems processing 
range: 20 L to 800 L
• Manual assemblies are usually used to 
accommodate volumes below 20 L
• The CS1000 system used here
• Intuitive and easy to use user interface
• Methods are easily configurable and 
automated – alarms in place 
• Pressure monitors, flow monitors, and 
conductivity monitors available to 
characterize process performance
CS1000 System 
Tube ID ½ in.
Cassette area 0.5 – 2.5 m2
Recirc. Pump capacity 20 – 1000 L/hr
Typical batch volumes 500 L 
Hold-up volume (volume 
in feed and retentate)
0.6 L
Operation Automatic
Large Scale Single-Use TFF 
9Transmembrane Pressure (TMP): 4-8 psi common
Large and small scale TFF had similar pressure profiles
Pressure limit for safe operation – 4 barg for reinforced manifold sections 
Pressure Profile for  Small (0.1m2) and Large Scale (2.5m2) TFF 
Runs
Large Scale Pressure Profile 
0
2
4
6
8
10
12
14
0 10 20 30 40 50 60 70 80 90
P
re
s
s
u
re
 (
p
s
i)
Throughput L/m2
Small Scale Pressure Profile
Feed Retentate Permeate TMP
10
Obtaining average permeate flux for small scale concentration
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Permeate Flux vs Volumetric Concentration
Average permeate flux = 54.8 LMH
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Average permeate flux = 40.7 LMH
Obtaining average permeate flux for small scale diafiltration
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Filter Sizing
Linear scale-up possible by extrapolating graph and deriving appropriate filter area
A = area
tT = total time
Vc = volume processed during concentration 
Vd = volume processed during diafiltration
Jc = avg. permeate flux during concentration
Jd = avg. permeate flux during diafiltration
A = 2.1 m2    2.5 m2 with ~20% safety factor 
Permeate flux from small scale concentration and diafiltration used to predict filter 
area for large scale
Processing time was kept similar for both scales
Predicted area for large scale = 2.1m2
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Comparable processing times at both 
scales 
Similar yield at both scales (within 
assay variability range)
Small and Large Scale Process Variables Comparison
Process Parameters Table
LMH = liters/meter2/ hour
LMM = liters/minute/ meter2
gc/cm2 = gene copies per centimeter2
Parameter
Small Scale Large Scale 
(~9 L Clarified bulk) (~200 L)
Processing time 
(concentration)
~1 h 30 m ~1 h 15 m
Processing time (buffer 
exchange)
~1 h 10 m ~1 h 5 m
Feed flux (concentration) 500 mL/min (300 LMH) 12.5 L/min (300 LMH)
Feed flux (buffer 
exchange)
500 mL/min (300 LMH) 12.5 L/min (300 LMH)
AVG Permeate flux  
(concentration)
54 LMH 60 LMH
AVG Permeate flow rate  
(buffer exchange)
40 LMH 38 LMH
Membrane surface area 0.1 m2 2.5 m2
Volume processed 9 L ~200 L
Titer (yield by qPCR) 99% 91%
Flow decay ~ 50% NA
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Recovery is in the 90% range for small and large scale TFF as tested by qPCR
Virus Recovery for Small and Large Scale and impurity clearance 
for small scale
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Process Yield for Small and Large Scale
SDS-page for starting load 
and permeate in small 
scale
Western for starting load 
and permeate in small 
scale
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Pall Virus Hardware Platform
Adherent seed train:
Xpansion multiplate bioreactor
Adherent bioreactor:
iCELLis 500 bioreactor 
Suspension seed train and bioreactor: 
Allegro STR 200, 1000 and
2000 L bioreactors
Clarification:
Stax depth filter systems 
Purification:
Allegro single-use chromatography system
Concentration:
Allegro single-use tangential 
flow filtration systems
Sterile filtration:
Allegro MVP single-use systemMedia/buffer storage/handling:
Allegro plastic/stainless steel totesMedia/buffer mixing:
Allegro 50L mixer, Mag Mixer
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TFF linear scalability from 9L to 200 L was successfully demonstrated. 
Pressures, processing times and yields at both scales were kept in the same 
range.
Pall has scalable TFF solutions for gene therapy application as well as other 
biologics. 
Conclusion 
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Pall PDS Global – Shared expertise on applications, harmonized procedures and
equipment portfolio ensuring the best service for our customers wherever the location
Process Development Services (PDS):
UK and US Development Laboratories
Portsmouth, United Kingdom
 200 m² of configurable BL2-grade suites
 Newly designed flexible laboratories 
 Equipped with Pall systems for suspension and adherent culture
 Latest innovations in Pall technology for large scale downstream 
processing (DSP)
 Advanced analytics on site including Q-TOF, H-Class Bio UPLC 
and Pall’s ForteBio Octet
®
systems
Westborough, Massachusetts, USA 
 500 m² of configurable laboratory space
 Class 10,000 cleanrooms and BL2-grade suites
 Newly designed laboratories with a focus on recombinant protein and cell therapy processes
 Advanced analytics on site including qPCR, Flow Cytometry, HPLC and Pall’s ForteBio Octet
®
systems
Ann Arbor, Michigan, USA
 200 m² of laboratory space
 Three rooms for BL-2 support 
 Focus on adherent microcarrier process development and training on techniques
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